285 related articles for article (PubMed ID: 33008499)
1. Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options.
Chakravarty D; Huang L; Kahn M; Tewari AK
Urol Clin North Am; 2020 Nov; 47(4):487-510. PubMed ID: 33008499
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Prostate Cancer: Treatments for the "Lethal" Phenotype.
Slovin SF
Urol Clin North Am; 2020 Nov; 47(4):469-474. PubMed ID: 33008497
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for Localized Prostate Cancer: The Next Frontier?
Patel D; McKay R; Parsons JK
Urol Clin North Am; 2020 Nov; 47(4):443-456. PubMed ID: 33008495
[TBL] [Abstract][Full Text] [Related]
4. Application of Single-Cell Sequencing to Immunotherapy.
Beaumont KG; Beaumont MA; Sebra R
Urol Clin North Am; 2020 Nov; 47(4):475-485. PubMed ID: 33008498
[TBL] [Abstract][Full Text] [Related]
5. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
6. Clinical development of immunotherapy for prostate cancer.
Noguchi M; Koga N; Igawa T; Itoh K
Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
[TBL] [Abstract][Full Text] [Related]
7. Prostate Cancer Immunotherapy-Finally in From the Cold?
Runcie KD; Dallos MC
Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy: a glimmer of hope for metastatic prostate cancer.
Jindal V
Chin Clin Oncol; 2018 Dec; 7(6):61. PubMed ID: 29860848
[TBL] [Abstract][Full Text] [Related]
9. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.
Collins JM; Redman JM; Gulley JL
Expert Rev Vaccines; 2018 Aug; 17(8):697-705. PubMed ID: 30058393
[TBL] [Abstract][Full Text] [Related]
10. Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.
Bryant G; Wang L; Mulholland DJ
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28714919
[TBL] [Abstract][Full Text] [Related]
11. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for prostate cancer.
Fong L; Small EJ
Semin Oncol; 2003 Oct; 30(5):649-58. PubMed ID: 14571412
[TBL] [Abstract][Full Text] [Related]
13. New prospectives of prostate cancer gene therapy: molecular targets and animal models.
Hsieh CL; Chung LW
Crit Rev Eukaryot Gene Expr; 2001; 11(1-3):77-120. PubMed ID: 11693967
[TBL] [Abstract][Full Text] [Related]
14. Combining immunotherapies for the treatment of prostate cancer.
Redman JM; Gulley JL; Madan RA
Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive review of immunotherapies in prostate cancer.
Maia MC; Hansen AR
Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer immunotherapy: where are we and where are we going?
De Velasco MA; Uemura H
Curr Opin Urol; 2018 Jan; 28(1):15-24. PubMed ID: 29095729
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade.
Mougel A; Terme M; Tanchot C
Front Immunol; 2019; 10():467. PubMed ID: 30923527
[TBL] [Abstract][Full Text] [Related]
18. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
[TBL] [Abstract][Full Text] [Related]
19. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
20. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
Stultz J; Fong L
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):697-717. PubMed ID: 33820953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]